Table 5.
Impact of iKIR2D genotype on clinic-biological variables and the outcome of total patients (MGUS+SMM+MM).
| |
2DL1+L2+L3+ (n=59 ) |
2DL1+L2−L3+ (n=76 ) |
2DL1+L2+L3− (n=18 ) |
2DL1−L2+L3− (n=12 ) |
|---|---|---|---|---|
| Age | ||||
| Years (Mean ± SEM ) | 65.4 ± 1.5 | 67.6 ± 1.5 | 64.7 ± 2.4 | 65.3 ± 5.24 |
| ≤47 years / >47 y (%) | 4/55 (6.8%) | 3/73 (3.9) | 1/16 (5.9%) | 3/9 (25.0%)1 |
| Plasma cell biology | ||||
| Histology-BMPC, % (Mean ± SEM ) | 11.3 ± 1.9 | 15.8 ± 2.2 | 19.9 ± 5.9 | 30.0 ± 7.2* |
| Monoclonal comp., g/dL (Mean ± SEM ) | 1.69 ± 0.18 | 1.77 ± 0.21 | 1.9 ± 0.5 | 2.9 ± 1.0 |
| Ratio aberrant/total-BMPC (Mean ± SEM ) | 81.2 ± 2.6 | 81.9 ± 2.5 | 87.8 ± 5.4 | 94.3 ± 2.4** |
| FISH alteration, no Yes/No (%)2 | 10/48 (42.6%) | 24/41 (36.9%) | 6/10 (37.5%) | 9/1 (90.0%)3 |
1
2DL1−L2+L3− vs. the other groups (p < 0.05; Pc > 0.05; OR = 5.99).
*
2DL1−L2+L3− vs. the other groups (p < 0.01; Pc < 0.05); 2DL1−L2+L3− vs. 2DL1+L2+L3+ (p < 0.01; Pc < 0.05).
**
2DL1−L2+L3− vs. the other groups (p < 0.05; Pc > 0.05); 2DL1−L2+L3− vs. 2DL1+L2+L3+ (p < 0.05; Pc > 0.05).
2
Any alteration of p53, 13q deletions, break of IgH or aneuploidy of Chr-5, -9 or -15.
3
2DL1−L2+L3− vs. the other groups (p < 0.001; Pc < 0.005; OR = 22.27).